Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accumulated Expenses (2016 - 2025)

Ultragenyx Pharmaceutical has reported Accumulated Expenses over the past 11 years, most recently at $265.0 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 9.96% to $265.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $265.0 million through Dec 2025, up 9.96% year-over-year, with the annual reading at $265.0 million for FY2025, 9.96% up from the prior year.
  • Accumulated Expenses was $265.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $220.5 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $265.0 million in Q4 2025 and troughed at $41.5 million in Q2 2021.
  • The 5-year median for Accumulated Expenses is $82.9 million (2023), against an average of $117.8 million.
  • Year-over-year, Accumulated Expenses soared 310.05% in 2022 and then plummeted 63.99% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $145.6 million in 2021, then plummeted by 45.77% to $78.9 million in 2022, then rose by 5.06% to $82.9 million in 2023, then soared by 190.59% to $241.0 million in 2024, then rose by 9.96% to $265.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Accumulated Expenses are $265.0 million (Q4 2025), $220.5 million (Q3 2025), and $61.1 million (Q2 2025).